P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)
Mika Kontro,
Timo Siitonen,
Johanna Rimpilainen,
Marja Pyorala,
Inka Pawlitzky,
Sofia Aakko,
Marie-Louise Fjaellskog,
Maija Hollmén,
Naval Daver
Affiliations
Mika Kontro
1 HUS, Hematology, Helsinki, Finland
Timo Siitonen
2 Oulu University Hospital, Hematology, Oulu, Finland
Johanna Rimpilainen
3 Tampere University Hospital, Hematology, Tampere, Finland
Marja Pyorala
4 Kuopio University Hospital, Hematology, Kuopio, Finland
Inka Pawlitzky
5 Faron Pharmaceuticals, Turku, Finland
Sofia Aakko
5 Faron Pharmaceuticals, Turku, Finland
Marie-Louise Fjaellskog
5 Faron Pharmaceuticals, Turku, Finland
Maija Hollmén
5 Faron Pharmaceuticals, Turku, Finland
Naval Daver
6 MD Anderson Main Building, Houston, United States
